AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8723300 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive auditory stimulation
Number of subjects: 10
Study 8723300 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral auditory stimulation
Number of subjects: 10
Study 8723300 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study 8723300 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 10
Study 1854361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (XU 62-320)
Number of subjects: 0
Study 6717701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate magnesium concentration in 12 patients
Number of subjects: 22
Study 31014176 — intervention group
Group type: EXPERIMENTAL
Intervention: Check Yourself (electronic screening and feedback tool)
Number of subjects: 84
Study 31014176 — intervention group
Group type: COMPARATOR
Intervention: Visit alone (control group)
Number of subjects: 84
Study 30281882 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Counselling (EAC)
Number of subjects: 513
Study 30281882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracing (TRIC)
Number of subjects: 513
Study 26872302 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week moderate-intensity exercise intervention (150 minutes of moderate-intensity aerobic exercise per week)
Number of subjects: 101
Study 26872302 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week moderate-intensity exercise intervention
Number of subjects: 101
Study 26872302 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 101
Study 23864069 — intervention group
Group type: EXPERIMENTAL
Intervention: Information with reminders
Number of subjects: 0
Study 23864069 — intervention group
Group type: EXPERIMENTAL
Intervention: Information with reminders and implementation intentions
Number of subjects: 0
Study 23864069 — intervention group
Group type: COMPARATOR
Intervention: Information alone
Number of subjects: 0
Study 22459628 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1506
Study 22459628 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 1506
Study 20090550 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting coronary stent system
Number of subjects: 600
Study 20090550 — intervention group
Group type: COMPARATOR
Intervention: Taxus Liberté Paclitaxel Eluting Coronary Stent System
Number of subjects: 600
Study 19102185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon
Number of subjects: 32
Study 19102185 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 32
Study 17768809 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 8
Study 17768809 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg/kg caffeine
Number of subjects: 8
Study 17768809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11828556 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited palmar incision CTR
Number of subjects: 72
Study 11828556 — intervention group
Group type: COMPARATOR
Intervention: Traditional open technique CTR
Number of subjects: 72
Study 10455342 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment starting at day 1
Number of subjects: 38
Study 10455342 — intervention group
Group type: COMPARATOR
Intervention: G-CSF treatment starting at day 6
Number of subjects: 38
Study 8569137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl and midazolam
Number of subjects: 0
Study 8569137 — intervention group
Group type: COMPARATOR
Intervention: Single dose application of fentanyl and midazolam
Number of subjects: 0
Study 2239569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg
Number of subjects: 84
Study 2239569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg
Number of subjects: 84
Study 725560 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk-Shiley valves
Number of subjects: 300
Study 725560 — intervention group
Group type: COMPARATOR
Intervention: Lillehei-Kaster valves
Number of subjects: 300
Study 725560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both valves
Number of subjects: 300
Study 31039812 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stent group (MSG)
Number of subjects: 76
Study 31039812 — intervention group
Group type: COMPARATOR
Intervention: Ordinary polymer stent group (OPSG)
Number of subjects: 76
Study 28479220 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department Electronic Medication Complete Communication (EMC2) Opioid Strategy with text messaging
Number of subjects: 0
Study 28479220 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department Electronic Medication Complete Communication (EMC2) Opioid Strategy without text messaging
Number of subjects: 0
Study 28479220 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26168409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm (six face-to-face sessions followed by nine telephone sessions)
Number of subjects: 170
Study 26168409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 170
Study 26168409 — intervention group
Group type: COMPARATOR
Intervention: Control arm (leaflet advising on healthy lifestyle)
Number of subjects: 170
Study 23513199 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 to 16 mm-long hydroxyapatite-coated implants after lateral sinus lifting with 50% organic bovine (Bio-Oss) and 50% autogenous bone (20 patients)
Number of subjects: 40
Study 23513199 — intervention group
Group type: COMPARATOR
Intervention: 8 mm implants after crestal sinus lifting with autogenous bone (20 patients)
Number of subjects: 40
Study 23513199 — intervention group
Group type: EXPERIMENTAL
Intervention: Long implants
Number of subjects: 40
Study 23513199 — intervention group
Group type: COMPARATOR
Intervention: Short implants
Number of subjects: 40
Study 21659406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation training for cricothyroidotomy
Number of subjects: 38
Study 19375849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 90
Study 19375849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17019629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alone/camera present
Number of subjects: 43
Study 17019629 — intervention group
Group type: EXPERIMENTAL
Intervention: Other present/camera present
Number of subjects: 43
Study 17019629 — intervention group
Group type: COMPARATOR
Intervention: Clinic observation
Number of subjects: 43
Study 17019629 — intervention group
Group type: COMPARATOR
Intervention: Home observation
Number of subjects: 43
Study 17019629 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly assessments
Number of subjects: 43
Study 15043515 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab pre-treated patients
Number of subjects: 313
Study 15043515 — intervention group
Group type: COMPARATOR
Intervention: Control group (infliximab naive)
Number of subjects: 313
Study 11813899 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tube (VT) only
Number of subjects: 20
Study 11813899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tube (VT) + Meniett
Number of subjects: 20
Study 9260418 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer Dyract
Number of subjects: 60
Study 9260418 — intervention group
Group type: COMPARATOR
Intervention: Hybrid composite resin Prisma TPH
Number of subjects: 60
Study 7917814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume lignocaine gel preparations (> 20 ml) with no antiseptic
Number of subjects: 106
Study 7917814 — intervention group
Group type: COMPARATOR
Intervention: Other preparations of lignocaine gel (exact details not specified)
Number of subjects: 106
Study 3048077 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fiber (HC, LF)
Number of subjects: 0
Study 3048077 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fiber (HC, HF)
Number of subjects: 0
Study 3048077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, low fiber (LC, LF)
Number of subjects: 0
Study 3048077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fiber (LC, HF)
Number of subjects: 0
Study 3048077 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of soy polysaccharide (10 g)
Number of subjects: 0
Study 31176669 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood protein biosignature consisting of 6 proteins
Number of subjects: 0
Study 31176669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 30901502 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) + Membrane Filtration (MF)
Number of subjects: 0
Study 30901502 — intervention group
Group type: COMPARATOR
Intervention: Immunoadsorption (IA) alone
Number of subjects: 0
Study 29141784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 412
Study 29141784 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 412
Study 29141784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium-DASH diet
Number of subjects: 412
Study 27342765 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/d
Number of subjects: 0
Study 27342765 — intervention group
Group type: COMPARATOR
Intervention: Choline intake of 480 mg/d
Number of subjects: 0
Study 22326568 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC) with low-lactose cow's milk
Number of subjects: 58
Study 22326568 — intervention group
Group type: EXPERIMENTAL
Intervention: Open oral challenge test with 200 mL of low-lactose cow's milk
Number of subjects: 58
Study 21212155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/day) + Gemcitabine (1200 mg/m² on days 1 and 8, every 21 days for a maximum of six cycles)
Number of subjects: 60
Study 21212155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/day) + Erlotinib (150 mg/day)
Number of subjects: 60
Study 19448383 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise (E)
Number of subjects: 50
Study 19448383 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised regular walking (W)
Number of subjects: 50
Study 16932240 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch (300 microg/day)
Number of subjects: 549
Study 16932240 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 549
Study 15271748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vellore regimen (combined glucose insulin and variable rate infusion)
Number of subjects: 204
Study 15271748 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing techniques)
Number of subjects: 204
Study 11357960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 7
Study 11357960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9374685 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1-(7-36) amide (0.4, 0.8, or 1.2 pmol.kg-1.min-1)
Number of subjects: 9
Study 9374685 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1-(7-37) (1.2 pmol.kg-1.min-1)
Number of subjects: 9
Study 9374685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9374685 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1-(7-36) amide and GLP-1-(7-37)
Number of subjects: 9
Study 8181617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxpentifylline
Number of subjects: 20
Study 8181617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3282032 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance chemotherapy
Number of subjects: 51
Study 3282032 — intervention group
Group type: COMPARATOR
Intervention: No postremission therapy (control)
Number of subjects: 51
Study 30146138 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing meditation (condition 1)
Number of subjects: 65
Study 30146138 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused meditation (condition 2)
Number of subjects: 65
Study 30146138 — intervention group
Group type: COMPARATOR
Intervention: Control condition (condition 3)
Number of subjects: 65
Study 26971257 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 simulated procedures
Number of subjects: 66
Study 26971257 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 simulated procedures
Number of subjects: 66
Study 26971257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 66
Study 23989970 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-up maneuver of manual lymphatic drainage
Number of subjects: 41
Study 23989970 — intervention group
Group type: EXPERIMENTAL
Intervention: Reabsorption maneuver of manual lymphatic drainage
Number of subjects: 41
Study 23989970 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 41
Study 22447850 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 28
Study 22447850 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 28
Study 22447850 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both medications
Number of subjects: 28
Study 20539246 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100-200 mg/d)
Number of subjects: 100
Study 20539246 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 100
Study 20539246 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 100
Study 20539246 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 100
Study 19128626 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated handout
Number of subjects: 51
Study 19128626 — intervention group
Group type: COMPARATOR
Intervention: Pure text handout
Number of subjects: 51
Study 19128626 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 51
Study 19128626 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated handout (1 year follow-up)
Number of subjects: 51
Study 15926058 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 33
Study 15926058 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy (MD)
Number of subjects: 33
Study 15926058 — intervention group
Group type: COMPARATOR
Intervention: One-level unilateral laminotomy
Number of subjects: 33
Study 15926058 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical procedures
Number of subjects: 33
Study 12784519 — intervention group
Group type: EXPERIMENTAL
Intervention: Marburger Rechtschreibtraining (spelling training program)
Number of subjects: 37
Study 12784519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tutoring)
Number of subjects: 37
Study 10933349 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting (group 1)
Number of subjects: 251
Study 10933349 — intervention group
Group type: COMPARATOR
Intervention: Systematic stenting (group 2)
Number of subjects: 251
Study 8610868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (100 IU = 2 mL) with bupivacaine 0.5% (5.5 mL) and lidocaine 2% (5.5 mL)
Number of subjects: 21
Study 8610868 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 0.5% (5.5 mL) and lidocaine 2% (5.5 mL) without hyaluronidase
Number of subjects: 21
Study 8438979 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education classes combined with a payroll‐based incentive system
Number of subjects: 10000
Study 3101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 0.2 mg/kg
Number of subjects: 6
Study 3101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 0.4 mg/kg
Number of subjects: 6
Study 3101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.1 mg/kg
Number of subjects: 6
Study 3101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 3.0 mg/kg
Number of subjects: 6
Study 3101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 3.0 mg/kg with morphine
Number of subjects: 6
Study 29785522 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 0
Study 29785522 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment
Number of subjects: 0
Study 27916213 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40mg once daily)
Number of subjects: 73
Study 27916213 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40mg twice daily for nonresponders)
Number of subjects: 73
Study 27916213 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (dose decreased by half for responders)
Number of subjects: 73
Study 27916213 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (dose increased for nonresponders)
Number of subjects: 73
Study 27916213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 24033480 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg dose of aspirin
Number of subjects: 20
Study 24033480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23979627 — intervention group
Group type: EXPERIMENTAL
Intervention: VF waveform analysis algorithm
Number of subjects: 987
Study 23979627 — intervention group
Group type: COMPARATOR
Intervention: Standard shock-first protocol
Number of subjects: 987
Study 20958958 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment for the elderly
Number of subjects: 0
Study 20958958 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 18953882 — intervention group
Group type: EXPERIMENTAL
Intervention: FTQ combined with cisplatin
Number of subjects: 119
Study 18953882 — intervention group
Group type: COMPARATOR
Intervention: Control group (tegafur + cisplatin)
Number of subjects: 119
Study 16185206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligence (IQ)
Number of subjects: 1799
Study 16185206 — intervention group
Group type: COMPARATOR
Intervention: Socio-economic position (SEP)
Number of subjects: 1799
Study 12939228 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women with coronary artery disease
Number of subjects: 2699
Study 10831008 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (220 microg)
Number of subjects: 351
Study 10831008 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (10 mg)
Number of subjects: 351
Study 10831008 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray
Number of subjects: 351
Study 10831008 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 351
Study 10831008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 351
Study 9019583 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study
Number of subjects: 3
Study 1732426 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 560 mg/m2 at 4-week intervals
Number of subjects: 0
Study 1732426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin 270 mg/m2 at 3-week intervals
Number of subjects: 0
Study 3891946 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phototherapy
Number of subjects: 22
Study 3891946 — intervention group
Group type: COMPARATOR
Intervention: Routine phototherapy (after serum bilirubin concentration reached 5 mg/dl)
Number of subjects: 22
Study 30412927 — intervention group
Group type: EXPERIMENTAL
Intervention: Geoff (painted anatomical horse)
Number of subjects: 45
Study 30412927 — intervention group
Group type: COMPARATOR
Intervention: Textbook (control)
Number of subjects: 45
Study 29216395 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM265 (400 mg oral dose) administered 3 days before CHMI
Number of subjects: 18
Study 29216395 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM265 (400 mg oral dose) administered 7 days before CHMI
Number of subjects: 18
Study 29216395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27086250 — intervention group
Group type: EXPERIMENTAL
Intervention: Association Splitting
Number of subjects: 84
Study 27086250 — intervention group
Group type: COMPARATOR
Intervention: Exercise Therapy
Number of subjects: 84
Study 24871652 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (electroacupuncture at the Hegu [LI4] and Zusanli [ST36] acupoints, as well as acupuncture at the Ear Shenmen)
Number of subjects: 60
Study 24871652 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (minimal acupuncture at the Hegu and Zusanli acupoints without electrical stimulation and superficial acupuncture at the Ear Shenmen)
Number of subjects: 60
Study 24871652 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 60
Study 22342199 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment
Number of subjects: 50
Study 22342199 — intervention group
Group type: COMPARATOR
Intervention: Open treatment
Number of subjects: 50
Study 19591010 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 1.0 mg
Number of subjects: 309
Study 19591010 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 0.5 mg
Number of subjects: 309
Study 19591010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 18417186 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopic eyes
Number of subjects: 0
Study 18417186 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration plaid stimuli
Number of subjects: 0
Study 18417186 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration plaid stimuli
Number of subjects: 0
Study 18417186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow-fixing eyes
Number of subjects: 0
Study 18417186 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 0
Study 15790044 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (800 mg/d for 28 days)
Number of subjects: 30
Study 15790044 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 30
Study 15463836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS)
Number of subjects: 0